FindMyKOL
Clinical trialNCT03056599CompletedPhase 1Interventional

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

NCT03056599 is a phase 1 interventional trial sponsored by Presage Biosciences. As of 21 Nov 2026, it is completed. It studies Multiple drug microinjection in Soft Tissue Sarcoma Adult. The registry lists an enrollment of 23 participants at 3 sites in 1 country. The registry lists a start date of 15 Dec 2016 and a primary completion date of 22 Jul 2021. One of its registered investigators has a FindMyKOL profile.

SponsorPresage BiosciencesEnrollment23Soft Tissue Sarcoma Adult
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03056599
FieldValue
Registry IDNCT03056599
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorPresage Biosciences
Enrollment23
Registered sites3
Countries1
ConditionsSoft Tissue Sarcoma Adult
DrugsMultiple drug microinjection
Start15 Dec 2016
Primary completion22 Jul 2021
Study completion22 Sept 2021
Last update posted24 Sept 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Monter Cancer Center (northwell Health)

    Lake Success

Oregon, United States1 site
  • Ohsu Knight Cancer Institute

    Portland

Washington, United States1 site
  • Fred Hutchinson Cancer Research Center/seattle Cancer Care Alliance (scca)/university of Washington

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregon: 1 siteOR1IdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Multiple drug microinjection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03056599

Each answer restates registry values shown on this page.

What is NCT03056599?

NCT03056599 is a phase 1 interventional trial sponsored by Presage Biosciences. It studies Multiple drug microinjection in Soft Tissue Sarcoma Adult.

Who leads NCT03056599?

The registry names Gary Deutsch, MD (principal investigator, Northwell Health), Kenneth Gundle, MD (principal investigator, Oregon Health & Science University (OHSU)) and Seth Pollack, MD (principal investigator, Fred Hutchinson Cancer Research Center/SCCA) as overall officials.

Where does NCT03056599 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03056599 study?

The registered drug and biological interventions are Multiple drug microinjection.

When did NCT03056599 end?

The registry lists a primary completion date of 22 Jul 2021 and a study completion date of 22 Sept 2021. The sponsor last updated the record on 24 Sept 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.